{"schema_version":"secwatch.filing_event.v1","accession":"0001562762-24-000179","form_type":"8-K","ticker":"CHE","cik":"0000019584","company_name":"CHEMED CORP","filed_at":"2024-07-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.272378+00:00","generated_at":"2026-05-31T17:19:53.039033+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Chemed Q2 adjusted EPS $5.47 (+34.1% YoY); raises FY2024 guidance to $23.55-$23.80","bullets":["Revenue $595.9M (+7.6%); GAAP EPS $4.65 (+32.5%); adjusted EPS $5.47 (+34.1%).","VITAS net patient revenue +16.7% to $374.6M; ADC +14.4% to 21,036; adjusted EBITDA +77% to $67.0M.","Roto-Rooter revenue -5% to $221.3M; adjusted EBITDA -9.2% to $59.8M; margin 27.0%.","FY2024 adjusted EPS guidance raised to $23.55-$23.80 (from $23.30-$23.70); VITAS EBITDA margin 19.3%-19.7%.","Repurchased 100k shares for $55.8M; cash $222.9M, no debt; $225.9M remaining buyback authorization."],"urls":{"canonical":"https://secwatch.observer/filing/0001562762-24-000179","json":"https://secwatch.observer/filing/0001562762-24-000179.json","markdown":"https://secwatch.observer/filing/0001562762-24-000179.md","text":"https://secwatch.observer/filing/0001562762-24-000179.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/19584/000156276224000179/0001562762-24-000179-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/19584/000156276224000179/che-20240724x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T17:19:53.039033+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}